Find Research Outputs

Search concepts
Selected Filters
2020

Mutational profiling in myelofibrosis: implications for management

Bose, P. & Verstovsek, S., Feb 1 2020, In : International journal of hematology. 111, 2, p. 192-199 8 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Mutation
Spliceosomes
Blast Crisis
Essential Thrombocythemia
2019
7 Citations (Scopus)

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Jain, P., Kantarjian, H., Boddu, P. C., Nogueras-González, G. M., Verstovsek, S., Garcia-Manero, G., Borthakur, G., Sasaki, K., Kadia, T. M., Sam, P., Ahaneku, H., O’Brien, S., Estrov, Z., Ravandi, F., Jabbour, E. & Cortes, J. E., Mar 26 2019, In : Blood Advances. 3, 6, p. 851-861 11 p.

Research output: Contribution to journalArticle

Open Access
Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Incidence
Confidence Intervals
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

Gotlib, J., Baird, J. H., George, T. I., Langford, C., Reyes, I., Abuel, J., Perkins, C., Schroeder, K., Bose, P. & Verstovsek, S., Jan 1 2019, In : Blood Advances. 3, 15, p. 2264-2271 8 p.

Research output: Contribution to journalArticle

Open Access
Systemic Mastocytosis
Mast Cells
Mastocytosis
Tryptases
Bone Marrow Cells
3 Citations (Scopus)

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Bose, P., Swaminathan, M., Pemmaraju, N., Ferrajoli, A., Jabbour, E. J., Daver, N., DiNardo, C., Alvarado, Y., Yilmaz, M., Huynh-Lu, J., Qiao, W., Wang, X., Matamoros Jr, A., Zhou, L., Pierce, S., Schroeder, K. D., Kantarjian, H. M. & Verstovsek, S., Jun 7 2019, In : Leukemia and Lymphoma. 60, 7, p. 1767-1774 8 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Histone Deacetylase Inhibitors
Palpation
Splenomegaly
INCB018424
11 Citations (Scopus)

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

Pemmaraju, N., Kantarjian, H., Nastoupil, L., Dupuis, M., Zhou, L., Pierce, S., Patel, K. P., Masarova, L., Cortes, J. & Verstovsek, S., May 23 2019, In : Blood. 133, 21, p. 2348-2351 4 p.

Research output: Contribution to journalArticle

Janus Kinases
Lymphoma
Neoplasms
Therapeutics
Second Primary Neoplasms

Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Ye, M. T., Wang, Y., Wang, S. A., Pemmaraju, N., Daver, N., Verstovsek, S., Zhang, Y., Zuo, Z., Medeiros, L. J. & You, M. J., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalLetter

Open Access
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Safety
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Generic Drugs

Emerging drugs for essential thrombocythemia

Masarova, L. & Verstovsek, S., Apr 3 2019, In : Expert Opinion on Emerging Drugs. 24, 2, p. 93-105 13 p.

Research output: Contribution to journalReview article

Essential Thrombocythemia
Pharmaceutical Preparations
Therapeutics
Histone Deacetylase Inhibitors
Telomerase

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms

Mughal, T. I., Pemmaraju, N., Radich, J. P., Deininger, M. W., Kucine, N., Kiladjian, J. J., Bose, P., Gotlib, J., Valent, P., Chen, C. C., Barbui, T., Rampal, R., Verstovsek, S., Koschmieder, S., Saglio, G. & Van Etten, R. A., Jan 1 2019, In : Hematological Oncology. 37, 3, p. 240-252 13 p.

Research output: Contribution to journalReview article

4'-N-benzoylstaurosporine
Hematology
Neoplasms
Education
Systemic Mastocytosis
1 Citation (Scopus)
Janus Kinase 2
Acute Myeloid Leukemia
Neoplasms
Primary Myelofibrosis
Mutation
3 Citations (Scopus)
Acute Myeloid Leukemia
Recurrence
Survival
Proteins
Disease-Free Survival
1 Citation (Scopus)

Myelofibrosis osteoclasts are clonal and functionally impaired

Veletic, I., Manshouri, T., Multani, A. S., Cameron Yin, C., Chen, L., Verstovsek, S. & Estrov, Z., May 23 2019, In : Blood. 133, 21, p. 2320-2324 5 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Osteoclasts
Bone
Osteosclerosis
Janus Kinase 2
5 Citations (Scopus)

New Concepts of Treatment for Patients with Myelofibrosis

Bose, P., Alfayez, M. & Verstovsek, S., Jan 1 2019, In : Current treatment options in oncology. 20, 1, 5.

Research output: Contribution to journalReview article

Primary Myelofibrosis
Janus Kinase 1
Janus Kinase 2
Therapeutics
Activin Receptors

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

Economides, M. P., Verstovsek, S. & Pemmaraju, N., Oct 1 2019, In : Current hematologic malignancy reports. 14, 5, p. 460-468 9 p.

Research output: Contribution to journalReview article

Clinical Trials
Neoplasms
Primary Myelofibrosis
Tumor Microenvironment
Telomerase
1 Citation (Scopus)
Leukemia, Myeloid, Chronic Phase
Therapeutics
ponatinib
Blood Vessels
Outcome Assessment (Health Care)

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis

Veletic, I., Manshouri, T., Newberry, K. J., Garnett, J., Verstovsek, S. & Estrov, Z., Apr 2019, In : British Journal of Haematology. 185, 2, p. 382-386 5 p.

Research output: Contribution to journalLetter

Primary Myelofibrosis
Tumor Burden
Survival
PTX3 protein

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes

Manshouri, T., Verstovsek, S., Harris, D. M., Veletic, I., Zhang, X., Post, S. M., Bueso-Ramos, C. E. & Estrov, Z., Jan 1 2019, In : PloS one. 14, 9, e0222912.

Research output: Contribution to journalArticle

Open Access
megakaryocytes
Primary Myelofibrosis
Megakaryocytes
monocytes
Monocytes

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

Santos, F. P. S., Getta, B., Masarova, L., Famulare, C., Schulman, J., Datoguia, T. S., Puga, R. D., Alves Paiva, R. D. M., Arcila, M. E., Hamerschlak, N., Kantarjian, H. M., Levine, R. L., Campregher, P. V., Rampal, R. K. & Verstovsek, S., Jan 1 2019, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Mutation
Survival
Genes
Leukocytosis
1 Citation (Scopus)

Renal complications of primary myelofibrosis

Strati, P., Glass, W. F., Abdelrahim, M., Selamet, U., Tchakarov, A., Workeneh, B. T., Verstovsek, S. & Abudayyeh, A., Jan 28 2019, In : Leukemia and Lymphoma. 60, 2, p. 507-510 4 p.

Research output: Contribution to journalLetter

Primary Myelofibrosis
Kidney

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis

Strati, P., Abdelrahim, M., Selamet, U., Page, V. D., Pierce, S. A., Verstovsek, S. & Abudayyeh, A., Jul 1 2019, In : Annals of hematology. 98, 7, p. 1611-1616 6 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Kidney
Multivariate Analysis
Confidence Intervals
Glomerular Filtration Rate
4 Citations (Scopus)

SMAC mimetics as potential cancer therapeutics in myeloid malignancies

Boddu, P., Carter, B. Z., Verstovsek, S. & Pemmaraju, N., Apr 1 2019, In : British Journal of Haematology. 185, 2, p. 219-231 13 p.

Research output: Contribution to journalReview article

Inhibitor of Apoptosis Proteins
Caspases
Mitochondria
Neoplasms
Therapeutics

SOHO State of the Art Updates and Next Questions: Myelofibrosis

Pettit, K., Verstovsek, S. & Talpaz, M., Apr 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia. 19, 4, p. 191-199 9 p.

Research output: Contribution to journalReview article

Primary Myelofibrosis
Clone Cells
Janus Kinase 2
Extramedullary Hematopoiesis
Hematopoietic Stem Cells
1 Citation (Scopus)

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

Saenz, D. T., Fiskus, W., Manshouri, T., Mill, C. P., Qian, Y., Raina, K., Rajapakshe, K., Coarfa, C., Soldi, R., Bose, P., Borthakur, G., Kadia, T. M., Khoury, J. D., Masarova, L., Nowak, A. J., Sun, B., Saenz, D. N., Kornblau, S. M., Horrigan, S., Sharma, S. & 4 others, Qiu, P., Crews, C. M., Verstovsek, S. & Bhalla, K. N., Jun 1 2019, In : Leukemia. 33, 6, p. 1373-1386 14 p.

Research output: Contribution to journalArticle

Catenins
Stem Cells
Neoplasms
Therapeutics
Apoptosis
Thrombocytosis
Primary Myelofibrosis
Polycythemia Vera
Thrombocytopenia
Signs and Symptoms

The Rationale for Immunotherapy in Myeloproliferative Neoplasms

Masarova, L., Bose, P. & Verstovsek, S., Aug 15 2019, In : Current hematologic malignancy reports. 14, 4, p. 310-327 18 p.

Research output: Contribution to journalReview article

Immunotherapy
Polycythemia Vera
Neoplasms
Primary Myelofibrosis
Immune System
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exons
Philadelphia Chromosome
Mutation
Neoplasms
5 Citations (Scopus)
Leukemia, Myelomonocytic, Chronic
Primary Myelofibrosis
Megakaryocytes
Mutation
Blood Cell Count
2018
3 Citations (Scopus)

A multimodality work-up of patients with Hypereosinophilia

Hu, Z., Boddu, P. C., Loghavi, S., Miranda, R. N., Goswami, M., Jeffrey, M. L., Tam, W., Orazi, A., Verstovsek, S. & Wang, S. A., Nov 2018, In : American journal of hematology. 93, 11, p. 1337-1346 10 p.

Research output: Contribution to journalArticle

Hypereosinophilic Syndrome
Platelet-Derived Growth Factor beta Receptor
Neoplasms
Molecular Biology
Bone Marrow
9 Citations (Scopus)
Azacitidine
Primary Myelofibrosis
Bone
Reticulin
Toxicity
4 Citations (Scopus)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

Couban, S., Benevolo, G., Donnellan, W., Cultrera, J., Koschmieder, S., Verstovsek, S., Hooper, G., Hertig, C., Tandon, M., Dimier, N., Malhi, V. & Passamonti, F., Sep 24 2018, In : Journal of Hematology and Oncology. 11, 1, 122.

Research output: Contribution to journalArticle

HhAntag691
Primary Myelofibrosis
Hematology
Medicine
Safety
16 Citations (Scopus)

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Assi, R., Kantarjian, H. M., Garcia-Manero, G., Cortes, J. E., Pemmaraju, N., Wang, X., Nogueras-Gonzalez, G., Jabbour, E., Bose, P., Kadia, T., Dinardo, C. D., Patel, K., Bueso-Ramos, C., Zhou, L., Pierce, S., Gergis, R., Tuttle, C., Borthakur, G., Estrov, Z., Luthra, R. & 3 others, Hidalgo-Lopez, J., Verstovsek, S. & Daver, N., Feb 1 2018, In : American journal of hematology. 93, 2, p. 277-285 9 p.

Research output: Contribution to journalArticle

Azacitidine
Myelodysplastic Syndromes
Neoplasms
Splenomegaly
INCB018424
5 Citations (Scopus)

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia

Khan, M., Muzzafar, T., Kantarjian, H., Badar, I., Short, N., Wang, X., Chamoun, K., Jain, P., DiNardo, C., Pemmaraju, N., Bose, P., Borthakur, G., Cortes, J., Verstovsek, S., Garcia-Manero, G. & Estrov, Z., Jul 1 2018, In : Annals of hematology. 97, 7, p. 1183-1191 9 p.

Research output: Contribution to journalArticle

Leukemia, Myelomonocytic, Chronic
Primary Myelofibrosis
Fibrosis
Survival
Neutrophils
6 Citations (Scopus)

Bone marrow findings in blast phase of polycythemia vera

Hidalgo López, J. E., Carballo-Zarate, A., Verstovsek, S., Wang, S. A., Hu, S., Li, S., Xu, J., Zuo, W., Tang, Z., Yin, C. C., Medeiros, L. J., Bueso-Ramos, C. E. & Tang, G., Mar 1 2018, In : Annals of hematology. 97, 3, p. 425-434 10 p.

Research output: Contribution to journalArticle

Blast Crisis
Polycythemia Vera
Bone Marrow
Primary Myelofibrosis
Karyotype
14 Citations (Scopus)

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations

Shah, M. Y., Ferracin, M., Pileczki, V., Chen, B., Redis, R., Fabris, L., Zhang, X., Ivan, C., Shimizu, M., Rodriguez-Aguayo, C., Dragomir, M., Van Roosbroeck, K., Almeida, M. I., Ciccone, M., Nedelcu, D., Cortez, M. A., Manshouri, T., Calin, S., Muftuoglu, M., Banerjee, P. P. & 24 others, Badiwi, M. H., Parker-Thornburg, J., Multani, A., Welsh, J. W., Estecio, M. R., Ling, H., Tomuleasa, C., Dima, D., Yang, H., Alvarez, H., You, M. J., Radovich, M., Shpall, E., Fabbri, M., Rezvani, K., Girnita, L., Berindan-Neagoe, I., Maitra, A., Verstovsek, S., Fodde, R., Bueso-Ramos, C., Gagea, M., Manero, G. G. & Calin, G. A., Apr 2018, In : Genome research. 28, 4, p. 432-447 16 p.

Research output: Contribution to journalArticle

Long Noncoding RNA
Single Nucleotide Polymorphism
RNA
Mutation
Neoplasms
1 Citation (Scopus)

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

Harrison, C. N., Griesshammer, M., Miller, C., Masszi, T., Passamonti, F., Zachee, P., Durrant, S., Pane, F., Guglielmelli, P., Verstovsek, S., Jones, M. M., Hunter, D. S., Sun, W., Li, J., Khan, M., Habr, D. & Kiladjian, J. J., Jul 2018, In : British Journal of Haematology. 182, 2, p. 279-284 6 p.

Research output: Contribution to journalLetter

Polycythemia Vera
INCB018424
4 Citations (Scopus)

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., Passamonti, F., Jones, M., Zhen, H., Li, J., Gadbaw, B., Perez Ronco, J., Khan, M. & Verstovsek, S., Apr 1 2018, In : Annals of hematology. 97, 4, p. 617-627 11 p.

Research output: Contribution to journalArticle

Interferons
Safety
Hydroxyurea
Polycythemia Vera
Phlebotomy
2 Citations (Scopus)

Kit Mutations: New Insights and Diagnostic Value

Falchi, L. & Verstovsek, S., Aug 2018, In : Immunology and Allergy Clinics of North America. 38, 3, p. 411-428 18 p.

Research output: Contribution to journalReview article

Systemic Mastocytosis
Mastocytosis
4'-N-benzoylstaurosporine
Mutation
Mast Cells
6 Citations (Scopus)
Blast Crisis
ponatinib
Cytogenetics
Protein-Tyrosine Kinases
Survival
5 Citations (Scopus)
GRB2 Adaptor Protein
Oligodeoxyribonucleotides
Hematologic Neoplasms
Cytarabine
Poisons
19 Citations (Scopus)
Primary Myelofibrosis
Reticulin
Fibrosis
Therapeutics
Splenomegaly
3 Citations (Scopus)

Management of Myelofibrosis-Related Cytopenias

Bose, P. & Verstovsek, S., Jun 1 2018, In : Current hematologic malignancy reports. 13, 3, p. 164-172 9 p.

Research output: Contribution to journalReview article

Primary Myelofibrosis
Anemia
Activin Receptors
Thalidomide
Thrombocytopenia
27 Citations (Scopus)

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Harrison, C. N., Vannucchi, A. M., Platzbecker, U., Cervantes, F., Gupta, V., Lavie, D., Passamonti, F., Winton, E. F., Dong, H., Kawashima, J., Maltzman, J. D., Kiladjian, J. J. & Verstovsek, S., Feb 2018, In : The Lancet Haematology. 5, 2, p. e73-e81

Research output: Contribution to journalArticle

Primary Myelofibrosis
Group Psychotherapy
Therapeutics
Spleen
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
4 Citations (Scopus)

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

Bose, P., Nazha, A., Komrokji, R. S., Patel, K. P., Pierce, S. A., Al-Ali, N., Sochacki, A., Shaver, A., Ma, W., Su, X., Daver, N. G., DiNardo, C. D., Garcia-Manero, G., Loghavi, S., Bueso-Ramos, C., Kantarjian, H. M., Sekeres, M. A., Savona, M. R., MacIejewski, J. P. & Verstovsek, S., Nov 8 2018, In : Blood. 132, 19, p. 2100-2103 4 p.

Research output: Contribution to journalLetter

Neoplasms

Myelofibrosis

Komrokji, R., Kuykendall, A., Padron, E. & Verstovsek, S., Nov 19 2018, Wintrobe's Clinical Hematology: Fourteenth Edition. Wolters Kluwer Health Pharma Solutions (Europe) Ltd, p. 5356-5393 38 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Primary Myelofibrosis
8 Citations (Scopus)

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

Strati, P., Tang, G., Duose, D. Y., Mallampati, S., Luthra, R., Patel, K. P., Hussaini, M., Mirza, A. S., Komrokji, R. S., Oh, S., Mascarenhas, J., Najfeld, V., Subbiah, V., Kantarjian, H., Garcia-Manero, G., Verstovsek, S. & Daver, N., Jul 3 2018, In : Leukemia and Lymphoma. 59, 7, p. 1672-1676 5 p.

Research output: Contribution to journalArticle

Leukemia
Neoplasms
Hematologic Neoplasms
Chromosome Aberrations
Disease-Free Survival
30 Citations (Scopus)

Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial

Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., Daly, R., Al-Fayoumi, S., Callahan, J. A., Singer, J. W., Gotlib, J., Jamieson, C., Harrison, C., Mesa, R. & Verstovsek, S., May 2018, In : JAMA Oncology. 4, 5, p. 652-659 8 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Randomized Controlled Trials
Therapeutics
INCB018424
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
8 Citations (Scopus)
Philadelphia Chromosome
Primary Myelofibrosis
Young Adult
Polycythemia Vera
Essential Thrombocythemia